44
Participants
Start Date
January 7, 2013
Primary Completion Date
December 31, 2017
Study Completion Date
December 31, 2017
Lanreotide
Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
Placebo (for sunitinib)
Sunitinib
Sunitinib 37.5 mg daily
CHU La Timone, Marseille
Hôpital Saint André, Bordeaux
Hopital Saint Vincent de Paul, Lille
Hôpital Edouard Herriot, Lyon
Hôpital St Antoine, Paris
Hôpital Beaujon, Clichy
Cliniques Universitaires Saint Luc, Brussels
Institut Jules Bordet, Brussels
ULB Erasme, Brussels
UZ Antwerpen, Edegem
UZ Gent, Ghent
UZ Leuven, Leuven
Hôpital Henri Mondor, Créteil
CHU Cochin, Paris
Hôpital Pitié Salpêtrière, Paris
Institut Mutualiste Montsouris, Paris
CHU Robert Debré, Reims
CHU Pontchaillou, Rennes
CHU Rouen, Rouen
CHRU Trousseau, Tours